BIOCON.NSBIOCON.NSNSE
Loading
EBITDA Margin Over TimeStable
Percentile Rank13
3Y CAGR-3.9%
5Y CAGR-1.8%
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

3Y CAGR
-3.9%/yr
vs -1.5%/yr prior
5Y CAGR
-1.8%/yr
Consistent
Acceleration
-2.5pp
Decelerating
Percentile
P13
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
1 yr
Consecutive growthStable
PeriodValueYoY Change
TTM21.08%+3.0%
202520.47%-7.7%
202422.17%-6.8%
202323.78%-0.5%
202223.91%+3.4%
202123.13%-8.6%
202025.31%+0.3%
201925.24%+25.8%
201820.06%-20.5%
201725.23%-